Table 1.

FDA and PMDA approval of SLC drugs from 2015 to 2018.

aSLC	bOther name	cDrug	dYear	Indication	Mechanism of action	References / Resources
SLC10A2	ASBT	Elobixibate (A3309)	2018	Chronic idiopathic constipation	Increases bile acid delivery to colon to accelerate and increase colonic secretion.	[8]
SLC5A2	SGLT2	SteglatroTM (ertugliflozin)	2017	Type II diabetes mellitus	Increases urinary glucose excretion via SGLT2 inhibition to reduce blood glucose levels.	iv
SLC18A2	VMAT2	Ingrezza™ (valbenazine)	2017	Tardive dyskinesia	Reversible inhibition of VMAT2 activity.	v
SLC18A2	VMAT2	Austedo™ (deutetrabenazine)	2017	Chorea associated with Huntington’s disease; Tardive dyskinesia	Mechanism of action for anti-chorea effects is currently unknown.	vi
SLC22A12	URAT1	Zurampic™ (lesinurad)	2015	Hyperuricemia associated with gout	Inhibition of URAT1 and organic anion transporter 4 (OAT4) (to a lesser extent), to increase uric acid excretion and reduce serum uric acid levels.	vii

^aSLC marks the primary SLC target of the newly approved drug

^bOther name corresponds to alternative name of the SLC gene or protein

^cDrug is the brand name of the drug with the generic name in parenthesis

^dYear marks the approval year of the drug by the FDA

^eElobixibat is a PMDA-approved drug. All others are FDA-approved.